NL192520C - Gesubstitueerde tetrahydrofuranderivaten met anti-PAF-werking, werkwijze voor hun bereiding en farmaceutische preparaten die hen bevat. - Google Patents
Gesubstitueerde tetrahydrofuranderivaten met anti-PAF-werking, werkwijze voor hun bereiding en farmaceutische preparaten die hen bevat. Download PDFInfo
- Publication number
- NL192520C NL192520C NL8800078A NL8800078A NL192520C NL 192520 C NL192520 C NL 192520C NL 8800078 A NL8800078 A NL 8800078A NL 8800078 A NL8800078 A NL 8800078A NL 192520 C NL192520 C NL 192520C
- Authority
- NL
- Netherlands
- Prior art keywords
- group
- alkyl
- formula
- carbon atoms
- atom
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 13
- 230000000694 effects Effects 0.000 title claims description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 title claims description 10
- 238000000034 method Methods 0.000 title claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 55
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 claims description 25
- 108010003541 Platelet Activating Factor Proteins 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 8
- 230000008602 contraction Effects 0.000 claims description 7
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 229960001340 histamine Drugs 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 125000006413 ring segment Chemical group 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 150000001351 alkyl iodides Chemical class 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 230000000702 anti-platelet effect Effects 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 125000005270 trialkylamine group Chemical group 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 22
- 239000007858 starting material Substances 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 9
- 230000008020 evaporation Effects 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- UQHSYJSAILMYCL-UHFFFAOYSA-N 2-tridecyl-2,3-dihydrofuran Chemical compound CCCCCCCCCCCCCC1CC=CO1 UQHSYJSAILMYCL-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 235000019256 formaldehyde Nutrition 0.000 description 5
- JVZRCNQLWOELDU-UHFFFAOYSA-N 4-Phenylpyridine Chemical compound C1=CC=CC=C1C1=CC=NC=C1 JVZRCNQLWOELDU-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 3
- CEDTWAXBIMRBDS-UHFFFAOYSA-N 2-hexyl-2,3-dihydrofuran Chemical compound CCCCCCC1CC=CO1 CEDTWAXBIMRBDS-UHFFFAOYSA-N 0.000 description 3
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 229960002887 deanol Drugs 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- CDHUYLPDPJKKMD-UHFFFAOYSA-N 2-hexadecyl-2,3-dihydrofuran Chemical compound CCCCCCCCCCCCCCCCC1CC=CO1 CDHUYLPDPJKKMD-UHFFFAOYSA-N 0.000 description 2
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 2
- JNTPTNNCGDAGEJ-UHFFFAOYSA-N 6-chlorohexan-1-ol Chemical compound OCCCCCCCl JNTPTNNCGDAGEJ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- GDCXBZMWKSBSJG-UHFFFAOYSA-N azane;4-methylbenzenesulfonic acid Chemical compound [NH4+].CC1=CC=C(S([O-])(=O)=O)C=C1 GDCXBZMWKSBSJG-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- AHOJTPZHHMJMCW-UHFFFAOYSA-N 1-ethylpiperidin-4-ol Chemical compound CCN1CCC(O)CC1 AHOJTPZHHMJMCW-UHFFFAOYSA-N 0.000 description 1
- DXZCEQMWOYZDFP-UHFFFAOYSA-N 1-methylpiperidin-1-ium;iodide Chemical compound [I-].C[NH+]1CCCCC1 DXZCEQMWOYZDFP-UHFFFAOYSA-N 0.000 description 1
- -1 2,2,5-tri-substituted tetrahydrofuran compounds Chemical class 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- GVMTZIMCHHIXJZ-UHFFFAOYSA-N 2-(2-methylpropyl)-2,3-dihydrofuran Chemical compound CC(C)CC1CC=CO1 GVMTZIMCHHIXJZ-UHFFFAOYSA-N 0.000 description 1
- ULYQZOSHKXVWQF-UHFFFAOYSA-N 2-[2-(2-chlorophenyl)ethyl]-2,3-dihydrofuran Chemical compound ClC1=CC=CC=C1CCC1OC=CC1 ULYQZOSHKXVWQF-UHFFFAOYSA-N 0.000 description 1
- ONGOTIKKWHOPAR-UHFFFAOYSA-N 2-cyclopentyl-2,3-dihydrofuran Chemical compound C1CCCC1C1OC=CC1 ONGOTIKKWHOPAR-UHFFFAOYSA-N 0.000 description 1
- SLDNUFALUGNXBN-UHFFFAOYSA-N 2-icosyl-2,3-dihydrofuran Chemical compound CCCCCCCCCCCCCCCCCCCCC1CC=CO1 SLDNUFALUGNXBN-UHFFFAOYSA-N 0.000 description 1
- PYSGFFTXMUWEOT-UHFFFAOYSA-N 3-(dimethylamino)propan-1-ol Chemical compound CN(C)CCCO PYSGFFTXMUWEOT-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 101100231515 Caenorhabditis elegans ceh-13 gene Proteins 0.000 description 1
- 101100048447 Caenorhabditis elegans unc-4 gene Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000634212 Penia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- PQGAHNJECSVDEI-UHFFFAOYSA-N [CH2]CCCCC Chemical compound [CH2]CCCCC PQGAHNJECSVDEI-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- BFAKENXZKHGIGE-UHFFFAOYSA-N bis(2,3,5,6-tetrafluoro-4-iodophenyl)diazene Chemical compound FC1=C(C(=C(C(=C1F)I)F)F)N=NC1=C(C(=C(C(=C1F)F)I)F)F BFAKENXZKHGIGE-UHFFFAOYSA-N 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- WGXZDYPGLJYBJW-UHFFFAOYSA-N chloroform;propan-2-ol Chemical compound CC(C)O.ClC(Cl)Cl WGXZDYPGLJYBJW-UHFFFAOYSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-O hydron;quinoline Chemical compound [NH+]1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-O 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000023569 ischemic bowel disease Diseases 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 230000000956 myotropic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41B—SHIRTS; UNDERWEAR; BABY LINEN; HANDKERCHIEFS
- A41B11/00—Hosiery; Panti-hose
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Textile Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB878701727A GB8701727D0 (en) | 1987-01-27 | 1987-01-27 | Tetrahydrofuran derivatives |
| GB8701727 | 1987-01-27 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NL8800078A NL8800078A (nl) | 1988-08-16 |
| NL192520B NL192520B (nl) | 1997-05-01 |
| NL192520C true NL192520C (nl) | 1997-09-02 |
Family
ID=10611264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8800078A NL192520C (nl) | 1987-01-27 | 1988-01-14 | Gesubstitueerde tetrahydrofuranderivaten met anti-PAF-werking, werkwijze voor hun bereiding en farmaceutische preparaten die hen bevat. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US4888337A (fr) |
| JP (1) | JPS63192767A (fr) |
| KR (1) | KR900004696B1 (fr) |
| AR (1) | AR243888A1 (fr) |
| AT (1) | AT397800B (fr) |
| AU (1) | AU610787B2 (fr) |
| BE (1) | BE1000694A3 (fr) |
| CA (1) | CA1329205C (fr) |
| CH (1) | CH678426A5 (fr) |
| DE (1) | DE3802362A1 (fr) |
| DK (1) | DK36588A (fr) |
| ES (1) | ES2005504A6 (fr) |
| FI (1) | FI93727C (fr) |
| FR (2) | FR2609988B1 (fr) |
| GB (2) | GB8701727D0 (fr) |
| HK (1) | HK17993A (fr) |
| IE (1) | IE61326B1 (fr) |
| IN (1) | IN169175B (fr) |
| IT (1) | IT1221779B (fr) |
| LU (1) | LU87114A1 (fr) |
| MA (1) | MA21167A1 (fr) |
| MY (1) | MY102310A (fr) |
| NL (1) | NL192520C (fr) |
| NO (1) | NO173332C (fr) |
| NZ (1) | NZ223156A (fr) |
| OA (1) | OA08709A (fr) |
| PT (1) | PT86641B (fr) |
| SE (1) | SE467974B (fr) |
| SG (1) | SG125992G (fr) |
| TN (1) | TNSN88003A1 (fr) |
| ZA (1) | ZA8878B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8712694D0 (en) * | 1987-05-29 | 1987-07-01 | Scras | Tetrahydrofurans etc |
| GB8712693D0 (en) * | 1987-05-29 | 1987-07-01 | Scras | Tetrahydrofurans etc |
| ES2013834A6 (es) * | 1989-01-30 | 1990-06-01 | Uriach & Cia Sa J | Procedimiento para la obtencion de derivados 4-sustituidos de 2-alcoxitetrahidrofurano. |
| GB9009469D0 (en) * | 1990-04-27 | 1990-06-20 | British Bio Technology | Compounds |
| GB9104746D0 (en) * | 1991-03-06 | 1991-04-17 | British Bio Technology | Compounds |
| GB9114337D0 (en) * | 1991-07-03 | 1991-08-21 | British Bio Technology | Compounds |
| GB9122308D0 (en) * | 1991-10-21 | 1991-12-04 | British Bio Technology | Compounds |
| ES2062943B1 (es) * | 1993-03-23 | 1995-11-16 | Uriach & Cia Sa J | Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas. |
| KR100863572B1 (ko) | 2007-05-04 | 2008-10-15 | 충남대학교산학협력단 | 신규 페로몬 성 냄새 물질 및 이를 함유하는 돼지의 발정유도용 조성물 |
| US20120226002A1 (en) | 2011-03-04 | 2012-09-06 | Gelest Technologies, Inc. | Silicon compounds derived from furfuryl alcohols and methods of preparation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2185220A (en) * | 1938-08-17 | 1940-01-02 | Smith Kline French Lab | Medicinal agent |
| CH625784A5 (en) * | 1976-09-17 | 1981-10-15 | Ciba Geigy Ag | Microbicides |
| US4289884A (en) * | 1979-01-08 | 1981-09-15 | Shell Oil Company | Herbicidal tetrahydrofuran derivatives |
| DE3413996A1 (de) * | 1984-04-13 | 1985-10-24 | Bayer Ag, 5090 Leverkusen | Tetrahydrofuran-2-ylmethylamine |
| GB8712694D0 (en) * | 1987-05-29 | 1987-07-01 | Scras | Tetrahydrofurans etc |
| GB8712693D0 (en) * | 1987-05-29 | 1987-07-01 | Scras | Tetrahydrofurans etc |
-
1987
- 1987-01-27 GB GB878701727A patent/GB8701727D0/en active Pending
-
1988
- 1988-01-05 IN IN07/DEL/88A patent/IN169175B/en unknown
- 1988-01-06 ZA ZA8878A patent/ZA8878B/xx unknown
- 1988-01-11 MY MYPI88000021A patent/MY102310A/en unknown
- 1988-01-11 NZ NZ223156A patent/NZ223156A/xx unknown
- 1988-01-13 AR AR88309829A patent/AR243888A1/es active
- 1988-01-14 NL NL8800078A patent/NL192520C/nl not_active IP Right Cessation
- 1988-01-15 US US07/144,238 patent/US4888337A/en not_active Expired - Lifetime
- 1988-01-18 FI FI880190A patent/FI93727C/fi not_active IP Right Cessation
- 1988-01-20 SE SE8800171A patent/SE467974B/sv not_active IP Right Cessation
- 1988-01-21 CH CH202/88A patent/CH678426A5/fr not_active IP Right Cessation
- 1988-01-22 ES ES8800154A patent/ES2005504A6/es not_active Expired
- 1988-01-25 BE BE8800082A patent/BE1000694A3/fr active
- 1988-01-25 NO NO880294A patent/NO173332C/no not_active IP Right Cessation
- 1988-01-26 TN TNTNSN88003A patent/TNSN88003A1/fr unknown
- 1988-01-26 LU LU87114A patent/LU87114A1/fr unknown
- 1988-01-26 KR KR1019880000599A patent/KR900004696B1/ko not_active IP Right Cessation
- 1988-01-26 GB GB8801652A patent/GB2200634B/en not_active Expired - Fee Related
- 1988-01-26 MA MA21404A patent/MA21167A1/fr unknown
- 1988-01-26 IE IE18888A patent/IE61326B1/en not_active IP Right Cessation
- 1988-01-26 DK DK036588A patent/DK36588A/da not_active Application Discontinuation
- 1988-01-26 CA CA000557392A patent/CA1329205C/fr not_active Expired - Fee Related
- 1988-01-27 FR FR888800909A patent/FR2609988B1/fr not_active Expired
- 1988-01-27 IT IT19222/88A patent/IT1221779B/it active
- 1988-01-27 FR FR888800908A patent/FR2611139B1/fr not_active Expired
- 1988-01-27 OA OA59270A patent/OA08709A/fr unknown
- 1988-01-27 AU AU10760/88A patent/AU610787B2/en not_active Ceased
- 1988-01-27 JP JP63014781A patent/JPS63192767A/ja active Pending
- 1988-01-27 DE DE3802362A patent/DE3802362A1/de active Granted
- 1988-01-27 AT AT0016688A patent/AT397800B/de not_active IP Right Cessation
- 1988-01-27 PT PT86641A patent/PT86641B/pt not_active IP Right Cessation
-
1992
- 1992-12-10 SG SG1259/92A patent/SG125992G/en unknown
-
1993
- 1993-03-04 HK HK179/93A patent/HK17993A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL192520C (nl) | Gesubstitueerde tetrahydrofuranderivaten met anti-PAF-werking, werkwijze voor hun bereiding en farmaceutische preparaten die hen bevat. | |
| RU2129553C1 (ru) | Производные тиазолидиндиона, их получение и фармацевтическая композиция | |
| US3915996A (en) | Process for making benzopyrans | |
| FI78297C (fi) | Foerfarande foer framstaellning av farmaceutiskt anvaendbara teofyllinderivat. | |
| US6506911B2 (en) | Pyrano [3,2-d]-1,3-dioxin-8 ones | |
| FR2562892A1 (fr) | Nouveaux dihydropyridinyldicarboxylates amides et esters, utilisation de ces composes comme medicament, compositions pharmaceutiques comprenant de tels composes et procede pour la preparation de tels composes | |
| EP0249950B1 (fr) | Composés aromatiques | |
| NL8501826A (nl) | Nieuwe 1,4-dihydropyridinederivaten en zouten daarvan, werkwijze voor het bereiden van deze derivaten en zouten en farmaceutische preparaten die ze bevatten. | |
| EP0068171B1 (fr) | Dérivés de dihydropyridine | |
| NL8920307A (nl) | Stereospecifieke werkwijze voor de bereiding van enantiomeren van furo3,4-c-pyridine, aldus verkregen verbindingen en therapeutische preparaten die ze bevatten. | |
| NL7904957A (nl) | Op de 4-plaats gesubstitueerd thiazoloxamzuren en hun zouten en esters. | |
| FR2480284A1 (fr) | Amines antihypertensives, leur procede de preparation et compositions antihypertensives en contenant. | |
| NL192203C (nl) | Tetrahydrofuran- en tetrahydrothiofeenderivaten met werking tegen de bloedplaatjes activerende factor. | |
| US4845113A (en) | 2-substituted -1,4-dihydropyridines and pharmaceutical compositions containing them | |
| NL192573C (nl) | 2,5-Digesubstitueerde tetrahydrofuran- of tetrahydrothiofeenverbindingen met werking tegen de bloedplaatjesactiverende factor en farmaceutisch preparaat dat deze verbindingen bevat. | |
| US4997843A (en) | 2,4-disubstituted derivatives of tetrahydrofuran useful for the treatment of PAF mediated illnesses | |
| US4956384A (en) | 1,4:3,6-dianhydrosorbitol 2-mononitrate and 5-mononitrate esters and pharmaceutical compositions therefrom | |
| JP2640245B2 (ja) | １，４−ジヒドロピリジン誘導体 | |
| FR2711992A1 (fr) | Nouveaux dérivé hétérocycliques, procédé de préparation et composition pharmaceutique les contenant. | |
| JPS6352031B2 (fr) | ||
| JPH01313460A (ja) | Ｎ‐置換されたｎ‐アミノ‐ピロール | |
| Merijanian et al. | Steric effects of ortho substituents on acid-catalyzed cyclization of thiocyanatoacetophenones | |
| US4147871A (en) | Cyclohexanetetrol derivatives | |
| NZ228087A (en) | Imidazolinone derivatives; pharmaceutical compositions and preparatory processes | |
| US4463004A (en) | Dioxazabicyclic derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| CNR | Transfer of rights (patent application after its laying open for public inspection) |
Free format text: GREENLAND GMBH & CO. KG |
|
| BV | The patent application has lapsed | ||
| V1 | Lapsed because of non-payment of the annual fee |
Effective date: 20030801 |